Lentiviral effector pathways of TRIM proteins

DNA and Cell Biology

Volumn 33, Issue 4, 2014, Pages 191-197

  Turrini, Filippo ^a   Di Pietro, Andrea ^a   Vicenzi, Elisa ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; TRIM PROTEIN; TRIM28 PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CHROMOSOME 11; CYTOSKELETON; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANTIVIRAL AGENTS; HIV-1; HUMANS; IMMUNITY, INNATE; LENTIVIRUS; MODELS, IMMUNOLOGICAL; MULTIPROTEIN COMPLEXES; UBIQUITIN-PROTEIN LIGASES;

EID: 84897453171     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2014.2374     Document Type: Article

References (57)

1. Allouch, A., Di Primio, C., Alpi, E., Lusic, M., Arosio, D., Giacca, M., et al. (2011). The TRIM family protein KAP1 inhibits HIV-1 integration. Cell Host Microbe 9, 484-495.
2. Asaoka, K., Ikeda, K., Hishinuma, T., Horie-Inoue, K., Takeda, S., and Inoue, S. (2005). A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun 338, 1950-1956.
3. Asper, M., Sternsdorf, T., Hass, M., Drosten, C., Rhode, A., Schmitz, H., et al. (2004). Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 78, 3162-3169.
4. Barr, S.D., Smiley, J.R., and Bushman, F.D. (2008). The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 4, e1000007.
5. Battivelli, E., Migraine, J., Lecossier, D., Matsuoka, S., Perez-Bercoff, D., Saragosti, S., et al. (2011). Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms. J Virol 85, 7828-7835.
6. Bernardi, R., and Pandolfi, P.P. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8, 1006-1016.
7. Bjorndal, A.S., Szekely, L., and Elgh, F. (2003). Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells. BMC Microbiol 3, 6.
8. Blondel, D., Kheddache, S., Lahaye, X., Dianoux, L., and Chelbi-Alix, M.K. (2010). Resistance to rabies virus infection conferred by the PMLIV isoform. J Virol 84, 10719-10726.
9. Bonilla, W.V., Pinschewer, D.D., Klenerman, P., Rousson, V., Gaboli, M., Pandolfi, P.P., et al. (2002). Effects of promyelocytic leukemia protein on virus-host balance. J Virol 76, 3810-3818.
10. Bouazzaoui, A., Kreutz, M., Eisert, V., Dinauer, N., Heinzelmann, A., Hallenberger, S., et al. (2006). Stimulated transacting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology 356, 79-94.
11. Carthagena, L., Bergamaschi, A., Luna, J.M., David, A., Uchil, P.D., Margottin-Goguet, F., et al. (2009). Human TRIM gene expression in response to interferons. PLoS One 4, e4894.
12. Chelbi-Alix, M.K., Quignon, F., Pelicano, L., Koken, M.H., and de The, H. (1998). Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 72, 1043-1051.
13. Di Pietro, A., Kajaste-Rudnitski, A., Oteiza, A., Nicora, L., Towers, G.J., Mechti, N., et al. (2013). TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol 87, 4523-4533.
14. Eldin, P., Papon, L., Oteiza, A., Brocchi, E., Lawson, T.G., and Mechti, N. (2009). TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol 90, 536-545.
15. Everett, R.D., and Chelbi-Alix, M.K. (2007). PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89, 819-830.
16. Fridell, R.A., Harding, L.S., Bogerd, H.P., Cullen, B.R. (1995). Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. Virology 209, 347-357.
17. Gack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., et al. (2009). Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5, 439-449.
18. Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., et al. (2007).TRIM25RING-fingerE3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916-920.
19. Gao, B., Duan, Z., Xu, W., and Xiong, S. (2009). Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50, 424-433.
20. Ghezzi, S., Galli, L., Kajaste-Rudnitski, A., Turrini, F., Marelli, S., Toniolo, D., et al. (2013). Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. Aids 27, 2335-2344.
21. Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S., and Bieniasz, P.D. (2004). Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 101, 10774-10779.
22. Iki, S., Yokota, S., Okabayashi, T., Yokosawa, N., Nagata, K., and Fujii, N. (2005). Serum-dependent expression of promyelocytic leukemia protein suppresses propagation of influenza virus. Virology 343, 106-115.
23. Kajaste-Rudnitski, A., Marelli, S.S., Pultrone, C., Pertel, T., Uchil, P.D., Mechti, N., et al. (2011). TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol 85, 5183-5196.
24. Kawai, T., and Akira, S. (2011). Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med 3, 513-527.
25. Keckesova, Z., Ylinen, L.M., and Towers, G.J. (2004). The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 101, 10780-10785.
26. Lusic, M., Marini, B., Ali, H., Lucic, B., Luzzati, R., and Giacca, M. (2013). Proximity to PML nuclear bodies regulates HIV-1 latency in CD4 + T cells. Cell Host Microbe 13, 665-677.
27. Mallery, D.L., McEwan, W.A., Bidgood, S.R., Towers, G.J., Johnson, C.M., and James, L.C. (2010). Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 107, 19985-19990.
28. McEwan, W.A., Tam, J.C., Watkinson, R.E., Bidgood, S.R., Mallery, D.L., and James, L.C. (2013). Intracellular antibodybound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14, 327-336.
29. McNab, F.W., Rajsbaum, R., Stoye, J.P., and O'Garra, A. (2011). Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 23, 46-56.
30. Nakayama, E.E., Miyoshi, H., Nagai, Y., and Shioda, T. (2005). A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J Virol 79, 8870-8877.
31. Ozato, K., Shin, D.M., Chang, T.H., and Morse, H.C., 3rd. (2008). TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8, 849-860.
32. Pampin, M., Simonin, Y., Blondel, B., Percherancier, Y., Chelbi-Alix, M.K. (2006). Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol 80, 8582-8592.
33. Perez-Caballero, D., Hatziioannou, T., Yang, A., Cowan, S., and Bieniasz, P.D. (2005). Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 79, 8969-8978.
34. Perfettini, J.L., Nardacci, R., Seror, C., Bourouba, M., Subra, F., Gros, L., et al. (2009). The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope. Cell Death Differ 16, 298-311.
35. Perron, M.J., Stremlau, M., Lee, M., Javanbakht, H., Song, B., and Sodroski, J. (2007). The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 81, 2138-2148.
36. Pertel, T., Hausmann, S., Morger, D., Zuger, S., Guerra, J., Lascano, J., et al. (2011). TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361-365.
37. Rajsbaum, R., Albrecht, R.A., Wang, M.K., Maharaj, N.P., Versteeg, G.A., Nistal-Villan, E., et al. (2012). Speciesspecific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog 8, e1003059.
38. Rajsbaum, R., Garcia-Sastre, A., and Versteeg, G.A. (2013). TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol [Epub ahead of print]; DOI: 10.1016/j.jmb.2013.12.005.
39. Regad, T., Saib, A., Lallemand-Breitenbach, V., Pandolfi, P.P., de The, H., and Chelbi-Alix, M.K. (2001). PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 20, 3495-3505.
40. Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., et al. (2001). The tripartite motif family identifies cell compartments. EMBO J 20, 2140-2151.
41. Roa, A., Hayashi, F., Yang, Y., Lienlaf, M., Zhou, J., Shi, J., et al. (2012). RING domain mutations uncouple TRIM5alpha restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J Virol 86, 1717-1727.
42. Rold, C.J., and Aiken, C. (2008). Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog 4, e1000074.
43. Rowe, H.M., Jakobsson, J., Mesnard, D., Rougemont, J., Reynard, S., Aktas, T., et al. (2010). KAP1 controls endogenous retroviruses in embryonic stem cells. Nature 463, 237-240.
44. Sanz-Ramos, M., and Stoye, J.P. (2013). Capsid-binding retrovirus restriction factors: discovery, restriction specificity and implications for the development of novel therapeutics. J Gen Virol 94, 2587-2598.
45. Sardiello, M., Cairo, S., Fontanella, B., Ballabio, A., and Meroni, G. (2008). Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties. BMC Evol Biol 8, 225.
46. Sawyer, S.L., Emerman, M., and Malik, H.S. (2007). Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog 3, e197.
47. Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., and Sodroski, J. (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853.
48. Stremlau, M., Perron, M., Lee, M., Li, Y., Song, B., Javanbakht, H., et al. (2006). Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103, 5514-5519.
49. Stremlau, M., Perron, M., Welikala, S., and Sodroski, J. (2005). Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 79, 3139-3145.
50. Tissot, C., and Mechti, N. (1995). Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 270, 14891-14898.
51. Uchil, P.D., Quinlan, B.D., Chan, W.T., Luna, J.M., and Mothes, W. (2008). TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4, e16.
52. Vaysburd, M., Watkinson, R.E., Cooper, H., Reed, M., O'Connell, K., Smith, J., et al. (2013). Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Natl Acad Sci U S A 110, 12397-12401.
53. Versteeg, G.A., Rajsbaum, R., Sanchez-Aparicio, M.T., Maestre, A.M., Valdiviezo, J., Shi, M., et al. (2013). The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 38, 384-398.
54. Wolf, D., and Goff, S.P. (2007). TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 131, 46-57.
55. Yap, M.W., Nisole, S., and Stoye, J.P. (2005). A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15, 73-78.
56. Zhang, F., Hatziioannou, T., Perez-Caballero, D., Derse, D., Bieniasz, P.D. (2006). Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353, 396-409.
57. Zhang, S., Guo, J.T., Wu, J.Z., and Yang, G. (2013). Identification and characterization of multiple TRIM proteins that inhibit hepatitis B virus transcription. PLoS One 8, e70001.